Physician profile
Mitchell S Akman
NPI 1831266345
$7,982.46
in general payments reported to CMS, 2019-2025
29 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,745 · 2020: $326 · 2021: $677 · 2022: $913 · 2023: $1,040 · 2024: $1,208 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.84 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,886.73 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,284.70 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $1,135.95 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $720.94 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Abbvie INC. | $399.09 | 2019-2025 | Synthroid |
| Astrazeneca Pharmaceuticals LP | $390.44 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $346.22 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $338.83 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $174.45 | 2019-2021 | |
| Corcept Therapeutics | $156.92 | 2019-2025 | Korlym |
| Medtronic, INC. | $128.95 | 2021-2024 | Minimed 780g |
| Insulet Corporation | $116.53 | 2019-2024 | Omnipod |
| Merck Sharp & Dohme LLC | $112.44 | 2019-2021 | |
| Abbott Laboratories | $103.34 | 2019-2024 | Freestyle Libre 3 |
| Medtronic Minimed, INC. | $99.60 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $86.37 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $79.50 | 2024-2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $59.07 | 2021-2022 | |
| Beta Bionics, INC. | $55.91 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Kyowa Kirin, INC. | $53.15 | 2023-2024 | Crysvita |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Eisai INC. | $37.41 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $36.50 | 2021-2024 | Gvoke Hypopen |
| Dexcom, INC. | $35.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.39 | 2019 | |
| Esperion Therapeutics, INC. | $21.66 | 2025 | Nexletol |
| Chiesi USA, INC. | $15.37 | 2025 | Mycapssa |
| Horizon Therapeutics Plc | $14.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Akman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.